The Italian Olon Group, a leading international supplier of active pharmaceutical ingredients (APIs), presents the 2023 Corporate Sustainability Report and confirms the...
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the...
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's...
Olon, an Italian CDMO and API producer of active pharmaceutical ingredients (APIs), plans to invest €10 million in a multi-year expansion of its production site in Mahad...
Olon Biotech, a division of Italian API producer Olon, has inaugurated a new facility for the industrial-scale production of proteins from alternative sources at its site...
Italian API producer Olon has started building a second facility at its Rodano site in Milan that will be entirely dedicated to producing ultra-potent compounds.
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi...
Major API supplier Olon is establishing a €10 million central R&D hub at its headquarters site in Roadano, near Milan. The Italian company said the facility paves the way...
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in...
